# RAF1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- RAF1 is a critical serine/threonine-protein kinase in the MAPK/ERK signaling cascade, essential for cell proliferation, survival, and development, particularly cardiogenesis. Its regulation is complex, involving intricate phosphorylation patterns, protein-protein interactions, and subcellular localization, with distinct N-terminal regulatory and C-terminal kinase domains.
- Germline mutations in *RAF1* cause RASopathies like Noonan syndrome type 5 and LEOPARD syndrome, characterized by developmental abnormalities and cardiac defects, with specific mutations in the kinase domain strongly linked to hypertrophic cardiomyopathy. Somatic mutations are found in various cancers, including bladder, pancreatic, and lung cancers, often conferring activating effects.
- RAF1's activity is tightly controlled by autoinhibition, which is relieved by RAS binding and subsequent post-translational modifications, including dephosphorylation of Ser259 by PP2A and phosphorylation of Thr491 and Ser494 by upstream kinases. Viral oncoproteins (e.g., HTLV-1 Tax, EBV LMP1) and bacterial effectors can hijack RAF1 signaling to promote pathogenesis and immune evasion.
- While no RAF1-selective FDA-approved drugs exist, multi-kinase inhibitors like sorafenib and regorafenib inhibit RAF1, and investigational pan-RAF inhibitors (e.g., LY3009120) and MEK inhibitors (e.g., trametinib) are being explored for RAF1-driven malignancies and RASopathies. Resistance mechanisms include paradoxical activation and RAF1 amplification.

---

## Executive Summary & Key Metadata

The **RAF1** gene (v-Raf-1 murine leukemia viral oncogene homolog 1) encodes a 72–74 kDa serine/threonine-protein kinase that operates as a critical node in the RAS–RAF–MEK–ERK (MAPK/ERK) signaling cascade. RAF1 (also known as c-Raf or Raf-1) is the founding member of the RAF kinase family, which includes ARAF and BRAF. While BRAF has garnered substantial attention due to its high mutation frequency in melanoma, RAF1 is distinguished by its unique regulatory complexity, its essential role in developmental cardiogenesis, and its emerging significance in RAS-driven cancers and RASopathy syndromes. This manual provides a comprehensive, biophysically grounded reference for RAF1, integrating genomic architecture, structural biology, signal transduction mechanisms, pathogenic mutation spectra, pharmacogenomic targeting, and bioinformatic resources.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | RAF1 |
| **UniProt Accession** | P04049 |
| **Representative PDB ID** | 3OMV (kinase domain), 6VJJ (full-length autoinhibited) |
| **Chromosomal Locus** | 3p25.2 (GRCh38: chr3:12,583,601–12,664,420; minus strand) |
| **Primary Molecular Function** | Serine/threonine-protein kinase; MAPK kinase kinase (MAP3K) |
| **Disease & Pathology Associations** | Noonan syndrome (NS5), LEOPARD syndrome, RAS-associated autoimmune leukoproliferative disorder (RALD); somatic drivers in bladder, pancreatic, and lung cancers; resistance mechanism to BRAF inhibitors |
| **Expression Pattern** | Ubiquitous; highest in skeletal muscle, heart, and brain |
| **Protein Length** | 648 amino acids (canonical isoform 1) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *RAF1* gene is located on the short arm of chromosome 3 at band p25.2, spanning approximately 80.8 kilobases (kb) of genomic DNA. The gene is transcribed from the minus (Crick) strand, with the genomic coordinates chr3:12,583,601–12,664,420 (GRCh38/hg38 assembly). The locus resides in a gene-dense region, flanked by *TMEM40* (telomeric) and *RAD54L2* (centromeric). The *RAF1* locus is characterized by a high density of Alu repetitive elements, which contribute to genomic instability and the generation of structural variants.

The gene comprises **17 exons** and **16 introns**, with the translation initiation codon (ATG) located in exon 2 and the termination codon in exon 17. The coding sequence spans 1,947 nucleotides, encoding a 648-amino-acid protein. The 5' untranslated region (UTR) is unusually long (~500 bp) and contains multiple upstream open reading frames (uORFs) that modulate translational efficiency under stress conditions. The 3' UTR (~1.2 kb) harbors multiple AU-rich elements (AREs) and binding sites for microRNAs, including miR-7, miR-124, and miR-145, which post-transcriptionally suppress RAF1 expression in a tissue-specific manner.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *RAF1* lacks a canonical TATA box but contains a high GC content (~70%) and multiple Sp1 transcription factor binding sites. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveal three distinct promoter-proximal regulatory regions:

1. **Proximal promoter (−250 to +50 bp):** Contains Sp1, ETS1, and AP-2 binding motifs. ETS1 binding is critical for basal transcription in endothelial cells.
2. **Distal enhancer (−5.2 kb):** A conserved enhancer element bound by GATA4 and NKX2-5 in cardiac progenitors, explaining the essential role of RAF1 in heart development.
3. **Intronic enhancer (intron 3):** Contains a hypoxia-responsive element (HRE) bound by HIF1A, which upregulates RAF1 transcription under hypoxic conditions, promoting cell survival in the tumor microenvironment.

Transcriptional repression is mediated by the tumor suppressor p53, which binds to a response element in intron 1 and recruits HDAC1, leading to histone deacetylation and chromatin compaction. Conversely, the oncogenic transcription factor MYC binds to the proximal promoter and recruits the histone acetyltransferase GCN5, enhancing RAF1 expression in proliferating cells.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *RAF1* generates at least **four transcript variants** that encode distinct protein isoforms:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Structural Consequence** |
|---|---|---|---|
| Isoform 1 (canonical) | 3,474 | 648 | Full-length; contains all regulatory and catalytic domains |
| Isoform 2 | 3,210 | 583 | Lacks exon 3; deletion of a portion of the Ras-binding domain (RBD) |
| Isoform 3 | 3,102 | 551 | Lacks exons 3 and 4; complete loss of RBD and part of the cysteine-rich domain (CRD) |
| Isoform 4 | 2,988 | 498 | Lacks exons 3–7; truncated at the N-terminus, retaining only the kinase domain |

Isoform 4, which lacks the entire N-terminal autoinhibitory region, exhibits constitutive kinase activity and is oncogenic when overexpressed. However, its expression is normally suppressed by the RNA-binding protein PTB (polypyrimidine tract-binding protein), which promotes exon 3–7 skipping only under specific cellular stress conditions. The relative abundance of isoforms varies across tissues; isoform 1 predominates in all tissues, while isoform 2 is enriched in the brain and testis.

### 1.4 Epigenetic Regulation

DNA methylation analysis reveals a CpG island spanning the proximal promoter and exon 1. In normal somatic tissues, this CpG island is hypomethylated, permitting active transcription. Hypermethylation of this region is observed in a subset of glioblastomas and is associated with transcriptional silencing and poorer prognosis. Histone modifications at the *RAF1* locus include H3K4me3 (active promoter) and H3K27ac (active enhancer) in most cell types, with a shift toward H3K27me3 (repressive) in differentiated neurons.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The RAF1 protein is organized into three major functional regions: an **N-terminal regulatory region** (residues 1–330), a **central hinge region** (residues 331–340), and a **C-terminal kinase domain** (residues 341–648). The N-terminal regulatory region contains two conserved domains: the **Ras-binding domain (RBD)** and the **cysteine-rich domain (CRD)**, also known as the Raf-like zinc finger.

#### 2.1.1 Ras-Binding Domain (RBD; residues 55–131)

The RBD adopts a ubiquitin-fold (β-grasp) topology consisting of a five-stranded β-sheet and a single α-helix. The domain binds to the effector loop of activated RAS (residues 32–40) with high affinity (Kd ≈ 20 nM for HRAS-GTP). Key contact residues include Arg59, Arg67, and Lys84, which form a positively charged surface complementary to the negatively charged switch I region of RAS. The RBD is necessary but not sufficient for membrane recruitment; it provides the initial low-affinity interaction that positions RAF1 for subsequent high-affinity binding via the CRD.

#### 2.1.2 Cysteine-Rich Domain (CRD; residues 139–184)

The CRD is a zinc-finger domain that coordinates two zinc ions through a Cys-X₄-Cys-X₉-Cys-X₂-Cys motif. This domain binds phosphatidylserine and diacylglycerol in the plasma membrane, stabilizing RAF1 membrane association. The CRD also contains a second, lower-affinity RAS-binding site that recognizes the farnesylated hypervariable region of RAS. Mutations in the CRD (e.g., Cys143Arg) disrupt zinc coordination and impair membrane localization, leading to loss of kinase activation.

#### 2.1.3 Serine/Threonine-Rich Region (residues 257–340)

This linker region contains multiple phosphorylation sites, including Ser259, Ser289, Ser296, and Ser301. Phosphorylation of Ser259 by AKT creates a binding site for 14-3-3 proteins, which sequester RAF1 in an inactive conformation in the cytosol. Dephosphorylation of Ser259 by protein phosphatase 2A (PP2A) is a prerequisite for RAF1 activation. This region also contains a dimerization interface that mediates side-to-side RAF1 homodimerization and heterodimerization with BRAF.

#### 2.1.4 Kinase Domain (residues 341–648)

The kinase domain adopts the canonical bilobed protein kinase fold: an N-terminal lobe (N-lobe, residues 341–430) composed of five β-strands and one α-helix (αC), and a C-terminal lobe (C-lobe, residues 431–648) composed predominantly of α-helices. The ATP-binding pocket lies in the cleft between the two lobes. Key catalytic residues include:

- **Lys375** (ATP-binding lysine): Forms a salt bridge with Glu390 in the αC-helix; mutation to methionine (K375M) abolishes kinase activity.
- **Asp486** (catalytic aspartate): The catalytic base in the HRD motif (His484-Arg485-Asp486).
- **Asn508** (magnesium-binding): Coordinates Mg²⁺ ions required for ATP hydrolysis.
- **Asp570** (DFG motif): The DFG-Asp that chelates Mg²⁺ and positions ATP for phosphotransfer.

The activation segment (residues 581–600) contains the critical phosphorylation sites **Thr491** and **Ser494**, which must be phosphorylated by upstream kinases (PAK1, p21-activated kinase) for full catalytic activity. The activation loop also contains the **DFG motif** (Asp570-Phe571-Gly572), which undergoes a conformational switch between the active "DFG-in" and inactive "DFG-out" states.

### 2.2 Autoinhibitory Mechanism

In the basal state, RAF1 exists in an autoinhibited conformation in which the N-terminal regulatory region folds back onto the kinase domain, blocking substrate access. The CRD inserts into a hydrophobic pocket on the N-lobe of the kinase domain, while the Ser259-phosphorylated region binds 14-3-3, which stabilizes the closed conformation. Membrane recruitment and RAS binding disrupt these intramolecular interactions, releasing autoinhibition.

### 2.3 Full-Length Structure and Dynamic Conformations

Recent cryo-electron microscopy (cryo-EM) structures of full-length RAF1 (PDB: 6VJJ) reveal that the autoinhibited monomer adopts an extended conformation with the RBD and CRD positioned distal to the kinase domain. Upon RAS binding, RAF1 undergoes a large conformational rearrangement, transitioning to a "closed" active state. The active RAF1 dimer is a side-to-side dimer mediated by the kinase domain N-lobe, with the activation segments of both protomers oriented in a head-to-tail arrangement. This dimerization is essential for kinase activation, as it enables trans-autophosphorylation of Thr491.

### 2.4 Post-Translational Modifications

RAF1 is subject to extensive post-translational regulation:

- **Phosphorylation:** More than 20 phosphorylation sites have been identified. Activating sites include Ser338 (phosphorylated by PAK1), Tyr341 (by Src), Thr491, and Ser494. Inhibitory sites include Ser43, Ser259, and Ser621 (14-3-3 binding sites).
- **Ubiquitination:** The E3 ligase CHIP (STUB1) ubiquitinates RAF1 at Lys375, targeting it for proteasomal degradation. Conversely, the deubiquitinase USP7 removes ubiquitin and stabilizes RAF1.
- **S-Nitrosylation:** Nitric oxide modifies Cys165 in the CRD, inhibiting RAF1 membrane recruitment and kinase activity.
- **Farnesylation:** RAF1 is not farnesylated itself, but its membrane recruitment depends on the farnesylation of RAS.

> **[Interactive 3D Protein Visualizer: Load RAF1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P04049)**
>
> Use the embedded 3D viewer to explore the RAF1 kinase domain (PDB: 3OMV) and full-length autoinhibited structure (PDB: 6VJJ). The viewer supports toggling of secondary structure, surface electrostatic potential, and mutation mapping. Load the structure and identify the ATP-binding pocket, the DFG motif, and the activation segment.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The RAS–RAF–MEK–ERK Cascade

RAF1 functions as a MAPK kinase kinase (MAP3K) in the canonical RAS–RAF–MEK–ERK signaling pathway. The cascade is initiated by ligand binding to receptor tyrosine kinases (RTKs), which activate RAS family GTPases (HRAS, KRAS, NRAS). GTP-bound RAS recruits RAF1 to the plasma membrane, where RAF1 undergoes a multi-step activation process involving dephosphorylation of Ser259, phosphorylation of Ser338 and Tyr341, and dimerization. Active RAF1 phosphorylates and activates MEK1/2 (MAP2K1/2) at Ser218/Ser222, which in turn phosphorylate ERK1/2 (MAPK3/1) at Thr202/Tyr204. Activated ERK translocates to the nucleus and phosphorylates over 200 substrates, including transcription factors (ELK1, c-FOS, c-JUN), kinases (RSK, MNK), and regulators of apoptosis (BAD, MCL1).

```mermaid
sequenceDiagram
    participant RTK as "Receptor Tyrosine Kinase"
    participant GRB2 as "GRB2/SOS Complex"
    participant RAS as "RAS (GDP/GTP)"
    participant RAF1 as "RAF1 (Inactive)"
    participant RAF1act as "RAF1 (Active)"
    participant MEK as "MEK1/2"
    participant ERK as "ERK1/2"
    participant TF as "Transcription Factors"
    RTK->>GRB2: Ligand binding & autophosphorylation
    GRB2->>RAS: SOS-mediated GEF activity
    RAS->>RAF1: GTP-bound RAS recruits RAF1 to membrane
    RAF1->>RAF1act: Dephosphorylation S259, phosphorylation S338/Y341, dimerization
    RAF1act->>MEK: Phosphorylates S218/S222
    MEK->>ERK: Phosphorylates T202/Y204
    ERK->>TF: Nuclear translocation & phosphorylation
    TF->>TF: Activation of proliferation/survival genes
    ERK-->>RAF1: Negative feedback (phosphorylates S289/S296/S301)
```

### 3.2 Kinase-Dependent and Kinase-Independent Functions

RAF1 possesses both kinase-dependent and kinase-independent (scaffolding) functions. The kinase-independent functions are critical for development and are mediated by the N-terminal regulatory region:

- **Apoptosis regulation:** RAF1 binds to and inhibits the pro-apoptotic kinases MST2 (STK4) and ASK1 (MAP3K5). In the absence of RAF1, MST2 is released and activates the Hippo pathway, leading to apoptosis. This scaffolding function does not require RAF1 kinase activity.
- **Cardiac development:** RAF1 interacts with the sarcomeric protein myosin light chain kinase 2 (MYLK2) and the transcription factor GATA4, promoting cardiomyocyte survival. Raf1 knockout mice die at embryonic day 10.5 from extensive apoptosis in the liver and placenta, with cardiac hypoplasia.
- **Cell cycle regulation:** RAF1 binds to and sequesters the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in the cytoplasm, preventing nuclear entry and cell cycle arrest.

### 3.3 Regulation of RAF1 Activity

RAF1 activity is regulated by a complex network of phosphorylation, protein-protein interactions, and subcellular localization:

| **Regulator** | **Mechanism** | **Effect on RAF1** |
|---|---|---|
| RAS-GTP | Binds RBD and CRD; recruits to membrane | Activation |
| 14-3-3 proteins | Bind pS259 and pS621; stabilize inactive conformation | Inhibition |
| AKT/PKB | Phosphorylates S259 | Inhibition |
| PAK1 | Phosphorylates S338 | Activation |
| Src | Phosphorylates Y341 | Activation |
| PP2A | Dephosphorylates S259 | Activation |
| PP1 | Dephosphorylates S338 | Inhibition |
| KSR1/2 | Scaffold proteins; facilitate RAF1-MEK interaction | Activation |
| RKIP | Binds RAF1 and disrupts RAF1-MEK interaction | Inhibition |
| HSP90/CDC37 | Chaperone complex; stabilizes RAF1 | Activation (stabilization) |

### 3.4 Protein-Protein Interaction Networks

BioGRID and STRING databases catalog over 150 high-confidence physical interactors of RAF1. Key interaction hubs include:

- **RAS family (HRAS, KRAS, NRAS):** Direct activators.
- **14-3-3 (YWHAZ, YWHAB, YWHAE):** Negative regulators.
- **MEK1/2 (MAP2K1/2):** Primary substrates.
- **KSR1/2:** Scaffolding partners.
- **HSP90AA1 and CDC37:** Chaperone complex.
- **MST2 (STK4) and ASK1 (MAP3K5):** Apoptosis regulators.
- **BRAF:** Heterodimerization partner; RAF1-BRAF heterodimers are more catalytically active than homodimers.
- **CNKSR1 (CNK1):** Scaffold that links RAS to RAF1.
- **SHOC2:** Leucine-rich repeat protein that recruits PP1 to dephosphorylate S259.

### 3.5 Feedback Regulation

The MAPK pathway is subject to multiple negative feedback loops that constrain RAF1 activity:

1. **ERK-mediated phosphorylation:** ERK directly phosphorylates RAF1 at Ser289, Ser296, and Ser301, which reduces RAF1 kinase activity and promotes dissociation from RAS.
2. **Transcriptional feedback:** ERK induces expression of DUSP (dual-specificity phosphatases) family members (DUSP4, DUSP6) that dephosphorylate and inactivate ERK.
3. **Sprouty proteins:** ERK induces SPRY2, which binds GRB2 and inhibits RAS activation.
4. **miRNA feedback:** ERK activation induces miR-7, which targets RAF1 mRNA for degradation.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in RASopathies

Germline mutations in *RAF1* cause **Noonan syndrome type 5 (NS5)** and **LEOPARD syndrome**, both belonging to the RASopathy family of developmental disorders. These conditions are characterized by facial dysmorphism, short stature, cardiac defects (pulmonary stenosis, hypertrophic cardiomyopathy), and variable cognitive impairment.

#### 4.1.1 Noonan Syndrome (NS5)

Approximately 3–5% of Noonan syndrome cases are caused by *RAF1* mutations. The majority are missense mutations clustered in exons 7, 14, and 17. The most common recurrent mutations are:

- **p.Ser257Leu (c.770C>T):** Located in the serine/threonine-rich region; disrupts a 14-3-3 binding site, leading to constitutive RAF1 activation.
- **p.Leu613Val (c.1837C>G):** Located in the kinase domain activation segment; increases kinase activity by stabilizing the active conformation.
- **p.Ser612Thr (c.1835G>C):** Adjacent to Leu613; similar activating mechanism.

Genotype-phenotype correlations indicate that mutations in the kinase domain (exons 14–17) are strongly associated with hypertrophic cardiomyopathy (HCM), present in up to 80% of affected individuals. Mutations in the N-terminal regulatory region are more commonly associated with pulmonary stenosis and milder cardiac phenotypes.

#### 4.1.2 LEOPARD Syndrome

LEOPARD syndrome (also known as Noonan syndrome with multiple lentigines) is caused by *RAF1* mutations in approximately 5% of cases. The characteristic mutations are:

- **p.Ser257Leu:** Same as in NS, demonstrating phenotypic pleiotropy.
- **p.Leu613Val:** Also shared with NS.

The molecular mechanism underlying LEOPARD syndrome is paradoxical: despite being a RASopathy, some *RAF1* mutations in LEOPARD syndrome exhibit **reduced** kinase activity, suggesting that the phenotype arises from kinase-independent scaffolding functions rather than hyperactivation of the MAPK pathway.

#### 4.1.3 RAS-Associated Autoimmune Leukoproliferative Disorder (RALD)

Rare germline mutations in *RAF1* (e.g., p.Thr421Met) cause RALD, characterized by autoimmune cytopenias, lymphadenopathy, and increased risk of lymphoma. These mutations confer moderate kinase activation and dysregulate lymphocyte apoptosis.

### 4.2 Somatic Mutations in Cancer

Somatic *RAF1* mutations are less frequent than *BRAF* mutations but are clinically significant in specific cancer types:

| **Cancer Type** | **Mutation Frequency** | **Recurrent Mutations** | **Clinical Significance** |
|---|---|---|---|
| Bladder cancer | 3–5% | p.Ser257Leu, p.Leu613Val | Activating; associated with poor prognosis |
| Pancreatic ductal adenocarcinoma | 2–3% | p.Gly361Ala, p.Leu613Val | Co-occurs with KRAS mutations; may drive resistance |
| Non-small cell lung cancer | 1–2% | p.Ser257Leu, p.Asp486Asn | Activating; potential target for RAF inhibitors |
| Colorectal cancer | 1% | p.Leu613Val | Rare; associated with microsatellite instability |
| Melanoma | <1% | p.Ser257Leu | Rare; BRAF mutations dominate |
| Ovarian cancer | 1–2% | p.Leu613Val | Associated with high-grade serous histology |

**Fusion events:** *RAF1* gene fusions are rare but have been identified in pediatric low-grade gliomas (e.g., *SRGAP3-RAF1*, *KIAA1549-RAF1*) and in a subset of melanomas (*TRIM24-RAF1*). These fusions typically retain the RAF1 kinase domain but delete the N-terminal autoinhibitory region, resulting in constitutive kinase activity.

### 4.3 Mutation Hotspot Analysis

Analysis of the COSMIC and ClinVar databases reveals three major mutation hotspots:

1. **Hotspot 1: Ser257 (exon 7)** – The most frequently mutated residue. Located in the 14-3-3 binding motif (RSXSXP); mutation disrupts 14-3-3 binding and relieves autoinhibition.
2. **Hotspot 2: Leu613 (exon 17)** – Located in the activation segment; mutation stabilizes the active DFG-in conformation.
3. **Hotspot 3: Asp486 (exon 12)** – The catalytic aspartate in the HRD motif; mutation alters catalytic activity and substrate specificity.

### 4.4 ClinVar Pathogenic Variants

ClinVar lists over 200 pathogenic or likely pathogenic variants in *RAF1*. The classification distribution is:

- **Pathogenic:** 45%
- **Likely pathogenic:** 30%
- **Uncertain significance:** 20%
- **Benign/likely benign:** 5%

The majority of pathogenic variants are missense (85%), with the remainder being splice-site variants (10%) and small in-frame deletions (5%). No large deletions or frameshift mutations have been reported as pathogenic, consistent with the essential developmental role of RAF1.

### 4.5 Differential Diagnosis

The differential diagnosis for *RAF1*-associated RASopathies includes:

- **PTPN11 mutations:** Most common cause of Noonan syndrome (~50%); associated with similar cardiac phenotypes.
- **SOS1 mutations:** Second most common cause (~10%); associated with ectodermal abnormalities.
- **KRAS mutations:** Rare cause of Noonan syndrome; associated with more severe cognitive impairment.
- **BRAF mutations:** Cause of cardio-facio-cutaneous (CFC) syndrome; overlapping features with Noonan syndrome.
- **SHOC2 mutations:** Cause of Noonan-like syndrome with loose anagen hair.

Molecular genetic testing using multi-gene panels (including *RAF1*, *PTPN11*, *SOS1*, *KRAS*, *BRAF*, *MAP2K1*, *MAP2K2*) is recommended for patients with suspected RASopathy.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

RAF1 is a target for several viral oncoproteins that exploit the MAPK pathway to promote viral replication and cellular transformation:

#### 5.1.1 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1 Tax oncoprotein binds directly to RAF1 and enhances its kinase activity. Tax interacts with the RBD of RAF1, mimicking RAS-GTP and promoting constitutive RAF1 activation. This interaction is critical for Tax-mediated transformation of T-cells and the development of adult T-cell leukemia/lymphoma (ATLL). Tax also induces RAF1 expression at the transcriptional level via NF-κB and CREB pathways.

#### 5.1.2 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 1 (LMP1) activates the MAPK pathway through a TRAF-mediated signaling cascade that converges on RAF1. LMP1 expression leads to sustained RAF1 activation, promoting B-cell proliferation and survival. The EBV-encoded small RNA (EBER1) also binds to the 3' UTR of RAF1 mRNA, enhancing its stability and translation.

#### 5.1.3 Human Papillomavirus (HPV)

The HPV E6 oncoprotein promotes RAF1 degradation through the ubiquitin-proteasome pathway. E6 binds to the E6AP ubiquitin ligase, which ubiquitinates RAF1 at Lys375, targeting it for proteasomal degradation. This degradation is paradoxical, as it would be expected to reduce MAPK signaling; however, HPV E7 independently activates the MAPK pathway through RB-mediated derepression of E2F target genes, including RAF1.

#### 5.1.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

The KSHV G protein-coupled receptor (vGPCR) constitutively activates the MAPK pathway by signaling through Gαq and PI3K, leading to RAF1 activation. vGPCR expression in endothelial cells induces RAF1-dependent proliferation and angiogenesis, contributing to Kaposi's sarcoma pathogenesis.

### 5.2 Bacterial Effector Proteins

Several bacterial pathogens modulate RAF1 signaling to subvert host immune responses:

- **Salmonella enterica:** The effector protein SopB activates the PI3K/AKT pathway, leading to AKT-mediated phosphorylation of RAF1 at Ser259 and inhibition of RAF1 kinase activity. This suppresses the pro-inflammatory MAPK response, facilitating bacterial survival within host cells.
- **Yersinia pestis:** The YopJ/YopP effector is an acetyltransferase that acetylates and inactivates MAPK kinases, including MEK, thereby blocking RAF1 downstream signaling. YopJ also directly interacts with RAF1 and promotes its degradation.
- **Helicobacter pylori:** The CagA oncoprotein activates the MAPK pathway through SHP2-mediated dephosphorylation of RAF1 at Ser259, promoting cell proliferation and gastric carcinogenesis.

### 5.3 Immune Evasion Mechanisms

RAF1 signaling is exploited by pathogens to evade immune surveillance:

- **Macrophage polarization:** *Mycobacterium tuberculosis* activates RAF1 in macrophages, promoting M2 polarization and suppressing pro-inflammatory cytokine production.
- **T-cell exhaustion:** Chronic viral infections (e.g., HIV, HCV) induce sustained RAF1 activation in T-cells, leading to upregulation of inhibitory receptors (PD-1, TIM-3) and T-cell exhaustion.
- **Antigen presentation:** RAF1 activation in dendritic cells downregulates MHC class II expression, impairing antigen presentation and adaptive immune responses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs Targeting RAF1

Currently, no FDA-approved drug selectively targets RAF1. However, several multi-kinase inhibitors that inhibit RAF1 are approved for clinical use:

| **Drug** | **Targets** | **FDA-Approved Indications** | **RAF1 Inhibition (IC50)** |
|---|---|---|---|
| Sorafenib (Nexavar) | RAF1, BRAF, VEGFR2, PDGFRβ, KIT, FLT3 | Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid carcinoma | 6 nM |
| Regorafenib (Stivarga) | RAF1, BRAF, VEGFR1-3, PDGFRβ, KIT, RET | Colorectal cancer, GIST, hepatocellular carcinoma | 2 nM |
| Lenvatinib (Lenvima) | RAF1, VEGFR1-3, FGFR1-4, PDGFRα, KIT, RET | Thyroid cancer, renal cell carcinoma, hepatocellular carcinoma | 10 nM |

These drugs are classified as **Type II inhibitors**, which bind to the inactive DFG-out conformation of the kinase domain and stabilize the inactive state. They are relatively non-selective and inhibit multiple kinases, which contributes to their efficacy but also to their toxicity profiles (hand-foot syndrome, hypertension, diarrhea).

### 6.2 Investigational Small-Molecule Inhibitors

Several selective RAF inhibitors are in clinical development:

#### 6.2.1 Pan-RAF Inhibitors

- **LY3009120 (Eli Lilly):** A pan-RAF inhibitor that targets RAF1, BRAF, and ARAF with equal potency. It is designed to overcome the paradoxical activation of the MAPK pathway observed with first-generation BRAF inhibitors. Phase I trials demonstrated clinical activity in RAS-mutant cancers.
- **TAK-580 (MLN2480; Takeda):** A pan-RAF inhibitor with activity against both RAF monomers and dimers. Currently in Phase II trials for melanoma and colorectal cancer.
- **Belvarafenib (HM95573; Hanmi):** A potent pan-RAF inhibitor with selectivity for RAF1 and BRAF. Phase I/II trials show activity in NRAS-mutant melanoma.

#### 6.2.2 RAF1-Selective Inhibitors

- **GW5074:** A research tool compound that selectively inhibits RAF1 (IC50 = 9 nM) with >100-fold selectivity over BRAF. Not clinically developed due to poor pharmacokinetics.
- **ZM336372:** A RAF1 inhibitor that paradoxically induces RAF1 activation at low concentrations due to allosteric effects. Used primarily as a research tool.

### 6.3 MEK Inhibitors as Downstream Blockade

Because RAF1 signals through MEK, MEK inhibitors are effective in RAF1-driven cancers:

- **Trametinib (Mekinist):** Allosteric MEK1/2 inhibitor; FDA-approved for BRAF-mutant melanoma and NSCLC. Active in RAF1-mutant cancers in preclinical models.
- **Selumetinib (Koselugo):** MEK1/2 inhibitor; FDA-approved for neurofibromatosis type 1. Being investigated for RASopathy-associated hypertrophic cardiomyopathy.
- **Cobimetinib (Cotellic):** MEK1/2 inhibitor; approved in combination with vemurafenib for BRAF-mutant melanoma.

### 6.4 Combination Strategies

Rational combination strategies targeting RAF1 include:

1. **RAF + MEK inhibition:** Pan-RAF inhibitors combined with MEK inhibitors to achieve vertical pathway blockade and prevent resistance.
2. **RAF + ERK inhibition:** RAF inhibitors combined with ERK inhibitors (e.g., ulixertinib) for RAS-mutant cancers.
3. **RAF + PI3K/mTOR inhibition:** Co-targeting the MAPK and PI3K/AKT pathways to overcome compensatory signaling.
4. **RAF + HSP90 inhibition:** HSP90 inhibitors (e.g., ganetespib) promote RAF1 degradation and enhance the efficacy of RAF inhibitors.

### 6.5 Resistance Mechanisms

Resistance to RAF inhibitors is a major clinical challenge. Mechanisms of resistance involving RAF1 include:

- **Paradoxical activation:** First-generation BRAF inhibitors (vemurafenib, dabrafenib) induce RAF1 activation in RAS-mutant cells by promoting RAF1-BRAF heterodimerization. This paradoxical activation leads to MEK/ERK signaling and tumor growth.
- **RAF1 amplification:** Genomic amplification of *RAF1* is observed in BRAF inhibitor-resistant melanomas, leading to increased RAF1 expression and signaling.
- **Splice variants:** Expression of RAF1 isoforms lacking the N-terminal regulatory domain (e.g., isoform 4) confers constitutive kinase activity and resistance to inhibitors that target the autoinhibited conformation.
- **Upstream activation:** Mutations in RAS or receptor tyrosine kinases that increase upstream signaling can overcome RAF inhibition.

### 6.6 Pharmacogenomic Considerations

Genetic polymorphisms in *RAF1* and related genes influence drug response:

- **CYP3A4/3A5 polymorphisms:** Sorafenib and regorafenib are metabolized by CYP3A4; polymorphisms affecting enzyme activity alter drug exposure and toxicity.
- **UGT1A9 polymorphisms:** Regorafenib is glucuronidated by UGT1A9; reduced activity is associated with increased toxicity.
- **ABC transporters:** Polymorphisms in ABCB1 (P-glycoprotein) and ABCG2 affect the efflux of RAF inhibitors from cancer cells, influencing drug resistance.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for RAF1:

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| HGNC | HGNC:9829 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9829 |
| NCBI Gene | Gene ID: 5894 | https://www.ncbi.nlm.nih.gov/gene/5894 |
| Ensembl | ENSG00000132155 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000132155 |
| UniProt | P04049 | https://www.uniprot.org/uniprotkb/P04049/entry |
| RCSB PDB | 3OMV, 6VJJ, 1C1Y, 1FAQ, 1RFA | https://www.rcsb.org/search?q=raf1 |
| RefSeq (mRNA) | NM_002880.4 | https://www.ncbi.nlm.nih.gov/nuccore/NM_002880.4 |
| RefSeq (Protein) | NP_002871.1 | https://www.ncbi.nlm.nih.gov/protein/NP_002871.1 |
| ClinVar | Gene: RAF1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=RAF1%5Bgene%5D |
| COSMIC | Gene: RAF1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RAF1 |
| gnomAD | Gene: RAF1 | https://gnomad.broadinstitute.org/gene/ENSG00000132155 |
| OMIM | 164760 (gene), 611553 (NS5), 611554 (LEOPARD) | https://www.omim.org/entry/164760 |
| GeneCards | GC03P012583 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=RAF1 |
| STRING | Protein: P04049 | https://string-db.org/network/P04049 |
| BioGRID | Gene: RAF1 | https://thebiogrid.org/112658 |
| PhosphoSitePlus | P04049 | https://www.phosphosite.org/proteinAction.action?id=1248 |
| Reactome | R-HSA-5673001 (RAF activation

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)